Investor Centre

Pharmaxis is pleased to announce top line results from the second large-scale global Phase III trial (CF302) of Bronchitol® (mannitol inhalation powder) in patients with cystic fibrosis (CF).

The results support the early and sustained improvement in lung function in cystic fibrosis patients seen in the first phase III study (CF301) and Pharmaxis will now move forward to meet the U.S. Food & Drug Administration (FDA) later this year to discuss a New Drug Application (NDA) for Bronchitol.